Oncolytics Biotech Inc Financials
This page shows Oncolytics Biotech Inc (ONCY) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Oncolytics is operating as a cash-consuming development company, with external financing bridging a roughly $20M annual operating shortfall.
Over the last two years, operating cash outflow stayed near$20M , so the business did not become cheaper to run. As cash on hand shrank to$5.2M , the company leaned on external financing, and that same dynamic pushed book equity below zero when liabilities overtook assets.
The widening operating loss was not driven by heavier research spending alone: R&D fell to
Near-term liquidity also tightened, with the current ratio dropping to 1.1x and cash covering less than one year of the recent burn pace. With total assets at
Financial Health Signals
Oncolytics Biotech Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Oncolytics Biotech Inc passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Oncolytics Biotech Inc reported a net loss of $28.8M while operations used $20.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Oncolytics Biotech Inc's EBITDA was -$28.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 12.6% from the prior year.
Oncolytics Biotech Inc reported -$28.8M in net income in fiscal year 2025. This represents a decrease of 26.2% from the prior year.
Oncolytics Biotech Inc earned -$0.30 per diluted share (EPS) in fiscal year 2025. That is unchanged from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Oncolytics Biotech Inc recorded an outflow of $20.1M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 0.3% from the prior year.
Oncolytics Biotech Inc held $5.2M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
None of these metrics is reported for fiscal year 2025.
Capital Allocation
Oncolytics Biotech Inc invested $13.3M in research and development in fiscal year 2025. This represents a decrease of 13.8% from the prior year.
Oncolytics Biotech Inc invested $6K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 96.6% from the prior year.
Not reported for fiscal year 2025.
ONCY Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 |
|---|---|---|
| R&D Expenses | $13.3M-13.8% | $15.4M |
| SG&A Expenses | $15.4M+52.6% | $10.1M |
| Operating Income | -$28.7M-12.5% | -$25.5M |
| Income Tax | $79K-16.8% | $95K |
| Net Income | -$28.8M-26.2% | -$22.8M |
| EPS (Diluted) | -$0.300.0% | -$0.30 |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense.
ONCY Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 |
|---|---|---|
| Total Assets | $7.6M-43.5% | $13.4M |
| Current Assets | $6.8M-45.0% | $12.4M |
| Cash & Equivalents | $5.2M-53.0% | $11.1M |
| Total Liabilities | $11.4M+12.4% | $10.1M |
| Current Liabilities | $6.1M+24.9% | $4.9M |
| Total Equity | -$3.8M-215.2% | $3.3M |
| Retained Earnings | -$429.5M-7.2% | -$400.7M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
ONCY Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 |
|---|---|---|
| Operating Cash Flow | -$20.1M-1.2% | -$19.9M |
| Capital Expenditures | $6K-96.6% | $174K |
| Free Cash Flow | -$20.1M-0.3% | -$20.1M |
| Investing Cash Flow | -$6K+96.6% | -$174K |
| Financing Cash Flow | $14.1M+180.8% | $5.0M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
ONCY Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 |
|---|---|---|
| Return on Equity | N/A | -691.1% |
| Return on Assets | -379.3%-209.5pp | -169.8% |
| Current Ratio | 1.12-1.4x | 2.55 |
| Debt-to-Equity | N/A | 3.07 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$3.8M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Where Oncolytics Biotech Inc Ranks
Frequently Asked Questions
Is Oncolytics Biotech Inc profitable?
No, Oncolytics Biotech Inc (ONCY) reported a net income of -$28.8M in fiscal year 2025.
What is Oncolytics Biotech Inc's EBITDA?
Oncolytics Biotech Inc (ONCY) had EBITDA of -$28.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Oncolytics Biotech Inc's free cash flow?
Oncolytics Biotech Inc (ONCY) recorded an outflow of $20.1M in free cash flow during fiscal year 2025. This represents a -0.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Oncolytics Biotech Inc's operating cash flow?
Oncolytics Biotech Inc (ONCY) recorded an outflow of $20.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Oncolytics Biotech Inc's total assets?
Oncolytics Biotech Inc (ONCY) had $7.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Oncolytics Biotech Inc's capital expenditures?
Oncolytics Biotech Inc (ONCY) invested $6K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Oncolytics Biotech Inc spend on research and development?
Oncolytics Biotech Inc (ONCY) invested $13.3M in research and development during fiscal year 2025.
What is Oncolytics Biotech Inc's current ratio?
Oncolytics Biotech Inc (ONCY) had a current ratio of 1.12 as of fiscal year 2025, which is considered adequate.
What is Oncolytics Biotech Inc's return on assets (ROA)?
Oncolytics Biotech Inc (ONCY) had a return on assets of -379.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Oncolytics Biotech Inc's cash runway?
Based on fiscal year 2025 data, Oncolytics Biotech Inc (ONCY) had $5.2M in cash against an annual operating cash burn of $20.1M. This gives an estimated cash runway of approximately 3 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Oncolytics Biotech Inc's debt-to-equity ratio negative or not reported?
Oncolytics Biotech Inc (ONCY) has negative shareholder equity of -$3.8M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Oncolytics Biotech Inc's Piotroski F-Score?
Oncolytics Biotech Inc (ONCY) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Oncolytics Biotech Inc's earnings high quality?
Oncolytics Biotech Inc (ONCY) reported a net loss of $28.8M while operations used $20.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.